Research progress of tumor vaccine in tumor immunotherapy

Wang Xinshuai, Qi Yanchao, Wang Yuandong

1. Clinical Oncology Center of Guangzhou Medical College and Guangzhou Cancer Hospital 2. Clinical Oncology Center of Guangzhou Medical College and Guangzhou Cancer Hospital 3. Clinical Oncology Center of Guangzhou Medical College and Guangzhou Cancer Hospital Guangdong Guangzhou 5100954. Guangdong Guangzhou 5100955. Guangdong Guangzhou 510095

Abstract: Immunotherapy of tumor has developed rapidly in recent years, and improving the immunogenicity of tumor and preparing efficient tumor vaccines have become a hot spot in immunotherapy. The most effective vaccine must be able to activate both CD4 T cells and CD8 T cells, so it is more meaningful to use a combination of MHC-class I and MHC-class II tumor antigens to prepare a tumor vaccine. This article reviews the immunological basis of tumor immunotherapy, tumor vaccines and the current status and progress of dendritic cell-based immunotherapy.

Key words:tumor vaccine;Immunotherapy;Dendritic cells;

• Album: Medical and Health Technology
• Special Topic: Oncology
• Classification number: R730.5

Research Progress of Tumor Vaccine in Tumor Immunotherapy_Wang Xinshuai. pdf